Shuvayu S. Sen

939 total citations
39 papers, 735 citations indexed

About

Shuvayu S. Sen is a scholar working on Orthopedics and Sports Medicine, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Shuvayu S. Sen has authored 39 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Orthopedics and Sports Medicine, 13 papers in Pathology and Forensic Medicine and 11 papers in Oncology. Recurrent topics in Shuvayu S. Sen's work include Bone health and osteoporosis research (19 papers), Bone health and treatments (9 papers) and Vitamin D Research Studies (8 papers). Shuvayu S. Sen is often cited by papers focused on Bone health and osteoporosis research (19 papers), Bone health and treatments (9 papers) and Vitamin D Research Studies (8 papers). Shuvayu S. Sen collaborates with scholars based in United States, Netherlands and United Kingdom. Shuvayu S. Sen's co-authors include Ron M. C. Herings, Paul Lips, M.J.M. Panneman, Tao Fan, Ankita Modi, Jackson Tang, Ethel S. Siris, Gert Bergman, G Nocea and Panagiotis Mavros and has published in prestigious journals such as PLoS ONE, Journal of General Internal Medicine and Bone.

In The Last Decade

Shuvayu S. Sen

39 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shuvayu S. Sen United States	16	417	255	192	126	92	39	735
M. Herson United States	8	533 1.3×	375 1.5×	186 1.0×	75 0.6×	193 2.1×	8	852
Annie Petrie Canada	11	304 0.7×	168 0.7×	134 0.7×	76 0.6×	63 0.7×	17	559
Eduard Sidelnikov Switzerland	13	137 0.3×	171 0.7×	108 0.6×	380 3.0×	82 0.9×	40	787
Manoj Chadha India	15	231 0.6×	281 1.1×	89 0.5×	42 0.3×	136 1.5×	40	796
Berthold Reichardt Austria	15	113 0.3×	201 0.8×	55 0.3×	32 0.3×	58 0.6×	66	636
Gabriel Raggio United States	9	311 0.7×	122 0.5×	246 1.3×	42 0.3×	69 0.8×	10	1.1k
Patrick Thiebaud United States	11	231 0.6×	109 0.4×	177 0.9×	25 0.2×	59 0.6×	14	649
Sukit Yamwong Thailand	16	59 0.1×	108 0.4×	89 0.5×	41 0.3×	75 0.8×	40	967
Allison Wyman United States	14	87 0.2×	222 0.9×	33 0.2×	19 0.2×	34 0.4×	26	656
Inna Sinuani Israel	16	61 0.1×	119 0.5×	26 0.1×	46 0.4×	90 1.0×	24	819

Countries citing papers authored by Shuvayu S. Sen

Since Specialization

Citations

This map shows the geographic impact of Shuvayu S. Sen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuvayu S. Sen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuvayu S. Sen more than expected).

Fields of papers citing papers by Shuvayu S. Sen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuvayu S. Sen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuvayu S. Sen. The network helps show where Shuvayu S. Sen may publish in the future.

Co-authorship network of co-authors of Shuvayu S. Sen

This figure shows the co-authorship network connecting the top 25 collaborators of Shuvayu S. Sen. A scholar is included among the top collaborators of Shuvayu S. Sen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuvayu S. Sen. Shuvayu S. Sen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Copley‐Merriman, Catherine, et al.. (2021). Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review. Adolescent Health Medicine and Therapeutics. Volume 12. 55–66. 16 indexed citations

Sarpong, Eric, et al.. (2020). <p>Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas</p>. Pediatric Health Medicine and Therapeutics. Volume 11. 421–428. 4 indexed citations

Laliberté, François, Monika Raut, Guillaume Germain, et al.. (2020). Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. Targeted Oncology. 16(1). 85–94. 2 indexed citations

Hooker, Gillian W., et al.. (2020). HSR20-083: Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the U.S.. Journal of the National Comprehensive Cancer Network. 18(3.5). HSR20–83. 1 indexed citations

Boon, Martijn, Chris H. Martini, Shuvayu S. Sen, et al.. (2018). Impact of high- versus low-dose neuromuscular blocking agent administration on unplanned 30-day readmission rates in retroperitoneal laparoscopic surgery. PLoS ONE. 13(5). e0197036–e0197036. 12 indexed citations

Prabhu, Vimalanand S., Joseph S. Solomkin, Goran Medić, et al.. (2017). Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States. Antimicrobial Resistance and Infection Control. 6(1). 107–107. 4 indexed citations

Kauf, Teresa L., Vimalanand S. Prabhu, Goran Medić, et al.. (2017). Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infectious Diseases. 17(1). 314–314. 12 indexed citations

Weaver, Jessica, et al.. (2017). Reasons for Not Treating Women with Postmenopausal Osteoporosis with Prescription Medications: Physicians' and Patients' Perspectives. Journal of Women s Health. 26(12). 1302–1311. 7 indexed citations

Modi, Ankita, Ethel S. Siris, Jackson Tang, & Shuvayu S. Sen. (2015). Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Current Medical Research and Opinion. 31(4). 757–765. 37 indexed citations

10.

Modi, Ankita, Jackson Tang, Shuvayu S. Sen, & Adolfo Díez‐Pérez. (2015). Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Current Medical Research and Opinion. 31(4). 767–777. 10 indexed citations

11.

Siris, Ethel S., et al.. (2013). Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Current Medical Research and Opinion. 30(1). 123–130. 29 indexed citations

12.

Arden, N K, Brett Hauber, F. Reed Johnson, et al.. (2012). How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with Osteoarthritis in the United Kingdom?. The Journal of Rheumatology. 39(5). 1056–1063. 22 indexed citations

13.

Sajjan, Shiva, et al.. (2011). Patterns of medication use for the treatment of menopausal symptoms before and after the women’s health initiative; implications for decision-making practices of women and women’s health professionals. Health. 3(7). 416–422. 1 indexed citations

14.

Chan, Siew Pheng, Boyd B. Scott, & Shuvayu S. Sen. (2010). An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: Physician and patient attitudes and beliefs. BMC Musculoskeletal Disorders. 11(1). 248–248. 15 indexed citations

15.

Linden, Michiel W. van der, Sabine Gaugris, Ernst J. Kuipers, et al.. (2009). COX‐2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety. 18(10). 880–890. 10 indexed citations

16.

Jansen, Jeroen P., Sabine Gaugris, Gert Bergman, & Shuvayu S. Sen. (2008). Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Current Medical Research and Opinion. 24(3). 671–684. 16 indexed citations

17.

Tellado, José M., Shuvayu S. Sen, M.T. Caloto, Ritesh Kumar, & G Nocea. (2007). Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scandinavian Journal of Infectious Diseases. 39(11-12). 947–955. 36 indexed citations

18.

Hanley, David A., et al.. (2007). Prescriptions for vitamin Damong patients taking antiresorptive agents in Canada. Current Medical Research and Opinion. 23(6). 1473–1480. 7 indexed citations

19.

Sen, Shuvayu S., Osvaldo Daniel Messina, Jorge Morales‐Torres, et al.. (2005). A risk assessment tool (OsteoRisk) for identifying latin American women with osteoporosis. Journal of General Internal Medicine. 20(3). 245–250. 35 indexed citations

20.

Borgström, Fredrik, Olof Johnell, Bengt Jönsson, Niklas Zethraeus, & Shuvayu S. Sen. (2004). Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone. 34(6). 1064–1071. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact